NZ535843A - Use of carbon-2-modified-19-nor-vitamin D analogs to induce the formation of new bone - Google Patents

Use of carbon-2-modified-19-nor-vitamin D analogs to induce the formation of new bone

Info

Publication number
NZ535843A
NZ535843A NZ535843A NZ53584303A NZ535843A NZ 535843 A NZ535843 A NZ 535843A NZ 535843 A NZ535843 A NZ 535843A NZ 53584303 A NZ53584303 A NZ 53584303A NZ 535843 A NZ535843 A NZ 535843A
Authority
NZ
New Zealand
Prior art keywords
bone
carbon
new bone
modified
analogs
Prior art date
Application number
NZ535843A
Other languages
English (en)
Inventor
Hector F Deluca
Wesley J Pike
Nirupama K Shevde
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28673538&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ535843(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of NZ535843A publication Critical patent/NZ535843A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
NZ535843A 2002-03-25 2003-03-12 Use of carbon-2-modified-19-nor-vitamin D analogs to induce the formation of new bone NZ535843A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/105,826 US20030195175A1 (en) 2002-03-25 2002-03-25 Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
PCT/US2003/007443 WO2003082300A1 (en) 2002-03-25 2003-03-12 Use of carbon-2-modified-vitamin d analogs to induce the formation of new bone

Publications (1)

Publication Number Publication Date
NZ535843A true NZ535843A (en) 2006-03-31

Family

ID=28673538

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ535843A NZ535843A (en) 2002-03-25 2003-03-12 Use of carbon-2-modified-19-nor-vitamin D analogs to induce the formation of new bone

Country Status (20)

Country Link
US (3) US20030195175A1 (https=)
EP (1) EP1494680B1 (https=)
JP (1) JP2005527558A (https=)
KR (1) KR100983953B1 (https=)
CN (1) CN100531739C (https=)
AT (1) ATE406901T1 (https=)
AU (1) AU2003220169B2 (https=)
BR (1) BR0308701A (https=)
CA (1) CA2480125C (https=)
DE (1) DE60323351D1 (https=)
DK (1) DK1494680T3 (https=)
ES (1) ES2312764T3 (https=)
HK (1) HK1079996B (https=)
IL (1) IL164275A0 (https=)
MX (1) MXPA04009288A (https=)
NZ (1) NZ535843A (https=)
PL (1) PL372346A1 (https=)
PT (1) PT1494680E (https=)
WO (1) WO2003082300A1 (https=)
ZA (1) ZA200408153B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027928A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vit amin d derivatives for the treatment of hypocalcemic tetany or hyproparathyroidism
WO2005027914A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
NZ545393A (en) * 2003-09-19 2009-10-30 Wisconsin Alumni Res Found 2-Alkylidene-19-nor-vitamin D derivatives for the treatment of osteopenia or male osteoporosis
WO2005027919A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
CA2539361A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
CA2563872C (en) * 2004-05-07 2014-11-25 Wisconsin Alumni Research Foundation Method of forming mesenchymal stem cells from embryonic stem cells
WO2006061683A1 (en) * 2004-12-09 2006-06-15 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteogenesis imperfecta
US7803789B2 (en) * 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
WO2010120698A1 (en) * 2009-04-17 2010-10-21 Vidasym, Llc Vitamin d receptor agonists and uses thereof
JP6971966B2 (ja) * 2015-08-05 2021-11-24 ウイスコンシン アラムニ リサーチ ファンデーション カルシトリオールの２−メチレン類似体および関連化合物の合成および生物活性
CN111588506B (zh) * 2020-01-02 2022-01-25 南京医科大学 一种含维生素c的钛种植体存储液的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US584928A (en) * 1897-06-22 Schlag
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
IL74617A (en) * 1985-03-15 1988-11-15 Yeda Res & Dev Compositions comprising a vitamin d derivative and method for the local treatment of bone fractures in animals
US5246925A (en) * 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5556645A (en) * 1990-01-12 1996-09-17 Bockman; Richard Methods of enhancing wound healing and tissue repair
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
DE69400495T2 (de) * 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
US5565589A (en) * 1993-11-03 1996-10-15 Wisconsin Alumni Research Foundation 17-formyl-5,6-trans-vitamin D compounds
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
JP3372259B2 (ja) * 1995-09-21 2003-01-27 ウィスコンシン・アルムニ・リサーチ・ファウンデーション カルシトリオール誘導体およびそれらの用途
US5976142A (en) * 1996-10-16 1999-11-02 Chin; Martin Apparatus and method for distraction osteogenesis of small alveolar bone
US6306844B1 (en) * 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
ES2320603T3 (es) * 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
WO2002005823A2 (en) * 2000-07-14 2002-01-24 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH

Also Published As

Publication number Publication date
EP1494680B1 (en) 2008-09-03
CA2480125C (en) 2009-12-29
ATE406901T1 (de) 2008-09-15
DK1494680T3 (da) 2008-11-17
US20030195175A1 (en) 2003-10-16
PT1494680E (pt) 2008-10-21
AU2003220169B2 (en) 2008-09-11
CA2480125A1 (en) 2003-10-09
CN100531739C (zh) 2009-08-26
KR20040095346A (ko) 2004-11-12
CN1655797A (zh) 2005-08-17
BR0308701A (pt) 2005-01-18
AU2003220169A1 (en) 2003-10-13
PL372346A1 (en) 2005-07-11
MXPA04009288A (es) 2005-06-08
DE60323351D1 (de) 2008-10-16
KR100983953B1 (ko) 2010-09-27
ES2312764T3 (es) 2009-03-01
ZA200408153B (en) 2006-03-29
IL164275A0 (en) 2005-12-18
JP2005527558A (ja) 2005-09-15
US20110112056A1 (en) 2011-05-12
WO2003082300A1 (en) 2003-10-09
HK1079996A1 (zh) 2006-04-21
EP1494680A1 (en) 2005-01-12
US20050203071A1 (en) 2005-09-15
HK1079996B (zh) 2010-04-01

Similar Documents

Publication Publication Date Title
Granströ et al. Bone-anchored reconstruction of the irradiated head and neck cancer patient
Jensen et al. Anterior maxillary alveolar distraction osteogenesis: a prospective 5-year clinical study.
NZ535843A (en) Use of carbon-2-modified-19-nor-vitamin D analogs to induce the formation of new bone
ATE365045T1 (de) Vermehrung des weich- sowie des knochengewebes anhand von aus muskeln stammenden vorläuferzellen,sowie damit verbundene zusammensetzungen und behandlungsformen
NO331024B1 (no) Anvendelse av risendroninsyre for forebygging eller behandling av osteoporose
MXPA05007181A (es) Cristales de la hormona de crecimiento humano y metodos para prepararlos.
IL153908A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 2alpha-METHYL-19-NOR-20(S)-1alpha, 25-DIHYDROXYVITAMIN D3
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
AR029157A1 (es) Compuestos heterociclicos, aromaticos utiles como secretagogos de la hormona del crecimiento y las composiciones farmaceuticas que los contienen
WO2004022529A3 (en) Diarylurea derivatives and their use as chloride channel blockers
WO2001015715A3 (en) Composition for maintenance of bone or dental health or treatment of bone or dental disorders
MXPA04004732A (es) Composiciones y estuches que comprenden un compuesto definido de boro, metodos para prepararlas y uso y administracion de las mismas.
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
AU2284001A (en) Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
BG106155A (en) Novel derivatives and analogues of galanthamin
GB2352972A (en) Use of dexmedetomidine for icu sedation
NO20060498L (no) Metode for a promotere benvekst
Kassolis et al. The segmental osteotomy in the management of malposed implants: a case report and literature review
MXPA03011626A (es) Derivados de quinazolina que promueven la liberacion de hormona paratiroides.
MX9805141A (es) Uso de inhibidores del intercambiador celular na+/h+ (nhe) para la preparacion de un farmaco para estimular la respiracion.
ATE198418T1 (de) Pharmazeutische zusammensetzung zur förderung der gewebeheilung und -regenerierung und darreichungssatz
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
WO2004019873A3 (en) Methods of promoting osteogenesis
Weinzweig et al. Immediate versus delayed midface distraction in a primate model using a new intraoral internal device
WO2004024083A3 (en) Methods of bone healing

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 MAR 2016 BY CPA GLOBAL

Effective date: 20130204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2017 BY CPA GLOBAL

Effective date: 20160129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2018 BY CPA GLOBAL

Effective date: 20170203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2019 BY CPA GLOBAL

Effective date: 20180201

LAPS Patent lapsed